CSE/DTC (CSE/DTC)

Canadian Securities Exchange: CSE/DTC · CAD

CA$0.35

+0.00 (0.0%)· Recorded snapshot

Market cap	26.5M
Net income (ttm)	-6M
EPS (ttm)	-CA$0.10
Shares out	75.8M
Volume	39,500
Beta	1.51

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -6M
EPS (ttm): -CA$0.10
Market cap: 26.5M

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-29 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-232.8

P25 n/aP50 n/aP75 n/a

ROIC-58

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All CSE/DTC indicators

Market & fundamental data

Available fields

150

Groups with data

Currency

CAD

Showing 150 of 150 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	CAD
Country	Canada
Country code	CA
Earnings date	2026-09-18
Enterprise value	CAD 25.1M
Exchange	Canadian Securities Exchange
Financial currency	CAD
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	June
Founded	2017
Industry	Biotechnology
Is primary listing	Yes
ISIN number	CA24463V1013
Last earnings date	2026-02-23
Last refreshed	2026-10-29
Market cap	CAD 26.5M
Price	CAD 0.35
Price currency	CAD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-29
Symbol	cse/DTC
Website	https://defencetherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-28.88%
FCF / EV yield	-18.09%
FCF yield	-17.15%
P/B ratio	4.9x
Price / tangible book value	4.9x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
ROA	-40.06%
ROA (5Y)	-193.22%
ROCE	-44.67%
ROE	-232.79%
ROIC	-58.04%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
Net income growth years	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	CAD -15,054
Depreciation and amortization	CAD 20,848
EBIT	CAD -3.8M
EBITDA	CAD -3.8M
EPS	CAD -0.10
FCF per share	CAD -0.06
Financing cash flow	CAD 5.4M
Free cash flow	CAD -4.5M
Free cash flow minus SBC	CAD -4.9M
Investing cash flow	CAD -30,052
Net borrowing	CAD 2M
Net cash flow	CAD 873,322
Net income	CAD -6M
Operating cash flow minus SBC	CAD -4.9M
Operating income	CAD -3.8M
Stock-based compensation	CAD 356,278

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	CAD 0.07
Debt / equity	0.29
Interest coverage	-13.06
Long-term assets	CAD 6.2M
Long-term liabilities	CAD 3.1M
Net cash (debt)	CAD 1.4M
Net cash / market cap	5.24%
Net cash growth	102.11%
Net debt / equity	-0.26
Piotroski F-Score	2
Property, plant and equipment	CAD 167,773
Shareholders' equity	CAD 5.4M
Tangible book value	CAD 5.4M
Tangible book value per share	CAD 0.07
Total assets	CAD 9.4M
Total cash	CAD 3M
Total debt	CAD 1.6M
Total liabilities	CAD 4M
WACC	12.67%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	CAD 3.3M
Current liabilities	CAD 973,684
Current ratio	3.37
Net working capital	CAD -648,137
Quick ratio	3.36
Working capital	CAD 2.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-34.05%
Shareholder yield	-34.05%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	CAD 0.48
1D price change	0%
1M price change	-12.5%
1M total return	-12.5%
1W price change	-4.11%
1W total return	-4.11%
1Y price change	-56.25%
1Y return CAGR	-56.27%
1Y total return	-56.25%
20-day SMA	CAD 0.38
200-day SMA	CAD 0.51
3M price change	-16.67%
3M total return	-16.67%
3Y price change	-87.85%
3Y return CAGR	-50.46%
3Y total return	-87.85%
50-day SMA	CAD 0.45
50-day SMA vs 200-day SMA	50under200
52-week high	CAD 0.93
52-week high date	2025-12-03
52-week low	CAD 0.34
52-week low date	2026-10-16
5Y price change	-94.53%
5Y return CAGR	-44.08%
5Y total return	-94.53%
6M price change	-32.69%
6M total return	-32.69%
All-time high	CAD 8.15
All-time high date	2021-09-10
All-time low	CAD 0.34
All-time low date	2026-10-14
Average true range (ATR)	CAD 0.03
Average volume	33.7K
Beta (1Y)	0.57
Beta (2Y)	0.22
Beta (5Y)	1.51
Change from 52-week high	-62.37%
Change from 52-week low	2.94%
Change from all-time high	-95.71%
Change from all-time low	2.94%
Change from open	-2.78%
Day's gap	2.86%
Dollar volume	CAD 13,825
High price	CAD 0.36
Low price	CAD 0.35
Monthly RSI	35.53
Open price	CAD 0.36
Position in 52-week range	0%
Previous close	CAD 0.35
Price vs 150-day SMA	-26.9%
Price vs 20-day SMA	-8.02%
Price vs 200-day SMA	-31.99%
Price vs 50-day SMA	-21.54%
Relative volume	1.17
RSI	41.52
Sharpe ratio	-0.65
Sharpe ratio (3Y)	-0.3
Sharpe ratio (5Y)	-0.21
Sortino ratio	-0.86
Sortino ratio (3Y)	-0.4
Sortino ratio (5Y)	-0.27
Volume	39.5K
Weekly RSI	37.99
YTD price change	-51.39%
YTD total return	-51.39%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	68M
Shares change (QoQ)	6.65%
Shares change (YoY)	34.05%
Shares held by insiders	10.24%
Shares outstanding	75.8M

Deeper analysis on CSE/DTC

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CSE/DTC report

Is a complete CSE/DTC research report available?

No complete published report is available for cse/DTC (CSE/DTC) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

CSE/DTC (CSE/DTC)

Price

Financial snapshot

Fair-value bridge

Latest news · CSE/DTC

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CSE/DTC indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CSE/DTC

Frequently asked questions